CAS, a division of the American Chemical Society specializing in scientific information solutions, announced today its CAS Life Sciences Advisory Board. The board comprises a world-class panel of global thought leaders, directing the CAS scientific journey to align authoritative content with groundbreaking predictive technologies that span the spectrum of life sciences workflows

The world’s most trusted source for scientific information, CAS, leverages new content, technologies, and expertise to advance its life sciences growth initiative.

Drawing on the CAS Content Collection and scientific expertise, CAS Insights offers business and research leaders perspectives on the latest developments across science and technology.

This collaboration leverages a tailored CAS Custom Services solution designed on a foundation of specialized CAS technologies, data science, and the CAS Content Collection to empower efficiencies in Dow’s research processes.

Through the CAS Innovation Incubator, CAS offers resources, expertise, and potential funding to early-stage innovators to help boost their science-based ventures.

CAS is launching a collaboration with Mana.bio to enrich their proprietary database to fuel its AI engine, with an expected 70% reduction in resources allocated to molecular data acquisition and preparation.

CAS has completed a project with The National Institute of Industrial Property (INPI) of Brazil for an enhanced examination workflow solution for chemistry patent applications using a unique blend of technology, artificial intelligence, data, and expertise. The new solution reduced application examination times by up to 50%, and helped to reduce their multi-year application backlog.

The CAS SciFinder Discovery Platform redefines its role in drug discovery with the inclusion of unique biosequence data collection and capabilities.

April19 and CAS collaborate to accelerate real-world application of AI to discovery of novel mental health therapeutics. Pairing curated data and advanced analytics with deep learning approach to drug discovery shortens pipeline and reduces cost.